Identification of a PCSK9-LDLR disruptor peptide with in vivo function

被引：32

作者：

Brousseau, Margaret E. ^{[1
]}

Clairmont, Kevin B. ^{[1
]}

Spraggon, Glen ^{[2
]}

Flyer, Alec N. ^{[1
]}

Golosov, Andrei A. ^{[1
]}

Grosche, Philipp ^{[3
]}

Amin, Jakal ^{[1
]}

Andre, Jerome ^{[3
]}

Burdick, Debra ^{[1
]}

Caplan, Shari ^{[1
]}

Chen, Guanjing ^{[1
]}

Chopra, Raj ^{[1
]}

Ames, Lisa ^{[1
]}

Dubiel, Diana ^{[1
]}

Fan, Li ^{[1
]}

Gattlen, Raphael ^{[3
]}

Kelly-Sullivan, Dawn ^{[1
]}

Koch, Alexander W. ^{[1
]}

Lewis, Ian ^{[3
]}

Li, Jingzhou ^{[1
]}

Liu, Eugene ^{[1
]}

Lubicka, Danuta ^{[1
]}

Marzinzik, Andreas ^{[3
]}

Nakajima, Katsumasa ^{[1
]}

Nettleton, David ^{[1
]}

Ottl, Johannes ^{[3
]}

Pan, Meihui ^{[1
]}

Patel, Tajesh ^{[1
]}

Perry, Lauren ^{[1
]}

Pickett, Stephanie ^{[3
]}

Poirier, Jennifer ^{[1
]}

Reid, Patrick C. ^{[4
]}

Pelle, Xavier ^{[3
]}

Seepersaud, Mohindra ^{[1
]}

Subramanian, Vanitha ^{[1
]}

Vera, Victoria ^{[1
]}

Xu, Mei ^{[1
]}

Yang, Lihua ^{[1
]}

Yang, Qing ^{[1
]}

Yu, Jinghua ^{[1
]}

Zhu, Guoming ^{[1
]}

Monovich, Lauren G. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, 22 Windsor St & 181 Massachusetts Ave, Cambridge, MA 02139 USA

[2] Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA

[3] Novartis Inst BioMed Res, Fabrikstr 2,Novartis Campus, CH-4056 Basel, Switzerland

[4] PeptiDream Inc, Meguro Ku, KOL Bldg,Room 405,4-6-1 Komaba, Tokyo 1538904, Japan

来源：

CELL CHEMICAL BIOLOGY | 2022年 / 29卷 / 02期

关键词：

SMALL-MOLECULE INHIBITORS; FACTOR-LIKE REPEAT; CRYSTAL-STRUCTURE; ANNEXIN A2; PROTEIN; DESIGN; BINDING; ANTIBODIES; DISPLAY; SITE;

D O I：

10.1016/j.chembiol.2021.08.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma low-density lipoprotein cholesterol (LDL-C) levels by promoting hepatic LDL receptor (LDLR) degradation. Therapeutic antibodies that disrupt PCSK9-LDLR binding reduce LDL-C concentrations and cardiovascular disease risk. The epidermal growth factor precursor homology domain A (EGF-A) of the LDLR serves as a primary contact with PCSK9 via a flat interface, presenting a challenge for identifying small molecule PCSK9-LDLR disruptors. We employ an affinity-based screen of 10(13) in vitro-translated macrocyclic peptides to identify high-affinity PCSK9 ligands that utilize a unique, induced-fit pocket and partially disrupt the PCSK9-LDLR interaction. Structure-based design led to molecules with enhanced function and pharmacokinetic properties (e.g., (13)PCSK9i). In mice,(13)PCSK9i reduces plasma cholesterol levels and increases hepatic LDLR density in a dose-dependent manner. (13)PCSK9i functions by a unique, allosteric mechanism and is the smallest molecule identified to date with in vivo PCSK9-LDLR disruptor function.

引用

页码：249 / +

页数：16

共 50 条

[41] THE PCSK9/LDLR AXIS IMPACTS INSULIN SECRETION AND GLUCOSE RESPONSE
Da Dalt, L.
Balzarotti, G.
Ruscica, M.
Bonacina, F.
Dhyani, A.
Di Cairano, E.
Baragetti, A.
Arnaboldi, L.
De Metrio, S.
Macchi, C.
Botta, M.
Uboldi, P.
Perego, C.
Catapano, A. L.
Norata, G. D.
ATHEROSCLEROSIS, 2018, 275 : E55 - E55
[42] PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Morales-Villegas, Enrique
CURRENT HYPERTENSION REVIEWS, 2013, 9 (04) : 310 - 323
[43] Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via LDLR
Huang, L.
Wu, H.
Wu, Y.
Song, F.
Zhang, L.
Li, Z.
Sun, H.
Huang, C.
JOURNAL OF DENTAL RESEARCH, 2022, 101 (01) : 83 - 92
[44] Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis
Cui, Jun
Qiu, Yuxiang
Kang, Ningsu
Lu, Jianxun
Zheng, Lu
JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (12): : 1430 - 1437
[45] Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
Poirier, Steve
Hamouda, Hocine Ait
Villeneuve, Louis
Demers, Annie
Mayer, Gaetan
PLOS ONE, 2016, 11 (06):
[46] PCSK9 function and physiology
Peterson, Andrew S.
Fong, Loren G.
Young, Stephen G.
JOURNAL OF LIPID RESEARCH, 2008, 49 (06) : 1152 - 1156
[47] Euphornin L promotes lipid clearance by dual regulation of LDLR and PCSK9
Li, Huihui
Li, Jun
Zhang, Xianjing
Li, Jiaomeng
Xi, Cong
Wang, Wenqiong
Lu, Youli
Xuan, Lijiang
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (06)
[48] Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2
Chae, Hee-Sung
Pel, Pisey
Cho, Jinwoo
Kim, Young-Mi
An, Chae-Yeong
Huh, Jungmoo
Choi, Young Hee
Kim, Jinwoong
Chin, Young-Won
JOURNAL OF ETHNOPHARMACOLOGY, 2021, 278
[49] Variation at the PCSK9 and LDLR locus, LDL levels, and heart disease in PROSPER
Polisecki, Eliana
Muallem, Hind
Maeda, Nolbuyo
Trompet, Stella
Julkema, Wouter
McMahon, Alex
Robetson, Michele
Ford, Ian
Blauw, Gerard
Murphy, Michael
Shepherd, James
Schaefer, Ernst
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E116 - E116
[50] The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nassoury, Nasha
Blasiole, Daniel A.
Oler, Angie Tebon
Benjannet, Suzanne
Hamelin, Josee
Poupon, Vivianne
McPherson, Peter S.
Attie, Alan D.
Prat, Annik
Seidah, Nabil G.
TRAFFIC, 2007, 8 (06) : 718 - 732

← 1 2 3 4 5 →